Abstract
Background
The massive scale-up of long-lasting insecticidal nets (LLIN) has led to a major reduction in malaria burden in many sub-Saharan African (SSA) countries. The World Health Organization (WHO) has recently issued a strong recommendation for the use of chlorfenapyr-pyrethroid LLINs compared to standard pyrethroid-only LLINs in areas of high insecticide resistance intensity. However, there is still a lack of conclusive evidence on the efficacy of piperonyl butoxide-pyrethroid (PBO-py) LLINs, especially in West Africa, where vector composition and resistance mechanisms may be different from vectors in East Africa.
Methods
This is a three-arm, superiority, triple-blinded, cluster randomised trial, with village as the unit of randomisation. This study conducted in Côte d’Ivoire will evaluate the efficacy on epidemiological and entomological outcomes of (1) the control arm: MAGNet® LN, which contains the pyrethroid, alpha-cypermethrin, (2) VEERALIN® LN, a net combining the synergist PBO and alpha-cypermethrin, and (3) Interceptor® G2 LN, which incorporates chlorfenapyr and alpha-cypermethrin, two adulticides with different mechanisms of action. A total of 33 villages with an average of 200 households per village will be identified, mapped, and randomised in a ratio of 1:1:1. Nets will be distributed at a central point following national guidelines with 1 net for every 2 people. The primary outcome of the trial will be incidence of malaria cases (confirmed by rapid diagnostic test (RDT)) in a cohort of 50 children aged 6 months to 10 years in each cluster, followed for 12 months (active case detection). Secondary outcomes are cross-sectional community prevalence of malaria infection (confirmed by RDT) in the study population at 6 and 12 months post-intervention (50 randomly selected persons per cluster), vector density, entomological inoculation rate (EIR), and phenotypic and genotypic insecticide resistance at baseline and 12 months post-intervention in 3 sentinel villages in each treatment arm.
Discussion
In addition to generating further evidence for next-generation LLINs, this study will also provide the first evidence for pyrethroid-PBO nets in a West African setting. This could further inform WHO recommendations on the pragmatic use of pyrethroid-PBO nets.
Trial registration
ClinicalTrials.gov NCT05796193. Registered on April 3, 2023.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Protopopoff, Natacha 2 ; Koffi, Alphonsine A. 3 ; Ahoua Alou, Ludovic P. 3 ; Dangbenon, Edouard 3 ; Messenger, Louisa A. 4 ; Kulkarni, Manisha A. 5 ; Zoh, Marius G. 3 ; Camara, Soromane 3 ; Assi, Serge B. 3 ; N’Guessan, Raphael 6 ; Cook, Jackie 7 1 London School of Hygiene and Tropical Medicine, Faculty of Epidemiology and Population Health, Department of Infectious Disease Epidemiology, London, UK (GRID:grid.8991.9) (ISNI:0000 0004 0425 469X)
2 London School of Hygiene and Tropical Medicine, Faculty of Infectious and Tropical Diseases, Disease Control Department, London, UK (GRID:grid.8991.9) (ISNI:0000 0004 0425 469X)
3 Institut Pierre Richet (IPR)/Institut National de Santé Publique (INSP), Bouaké, Côte d’Ivoire (GRID:grid.452477.7) (ISNI:0000 0005 0181 5559)
4 London School of Hygiene and Tropical Medicine, Faculty of Infectious and Tropical Diseases, Disease Control Department, London, UK (GRID:grid.8991.9) (ISNI:0000 0004 0425 469X); University of Nevada, Department of Environmental and Occupational Health, School of Public Health, Las Vegas, USA (GRID:grid.272362.0) (ISNI:0000 0001 0806 6926)
5 University of Ottawa, School of Epidemiology & Public Health, Faculty of Medicine, Ottawa, Canada (GRID:grid.28046.38) (ISNI:0000 0001 2182 2255)
6 London School of Hygiene and Tropical Medicine, Faculty of Infectious and Tropical Diseases, Disease Control Department, London, UK (GRID:grid.8991.9) (ISNI:0000 0004 0425 469X); Institut Pierre Richet (IPR)/Institut National de Santé Publique (INSP), Bouaké, Côte d’Ivoire (GRID:grid.452477.7) (ISNI:0000 0005 0181 5559)
7 London School of Hygiene and Tropical Medicine, Faculty of Epidemiology and Population Health, Department of Infectious Disease Epidemiology, London, UK (GRID:grid.8991.9) (ISNI:0000 0004 0425 469X); London School of Hygiene and Tropical Medicine, Medical Research Council (MRC) International Statistics and Epidemiology Group, London, UK (GRID:grid.8991.9) (ISNI:0000 0004 0425 469X)




